MWNA
CLDX icon

Marshall Wace North America’s Celldex Therapeutics CLDX Stock Holding History

Marshall Wace North America’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-24,261
Closed -$500K – 1495
2021
Q1 		$500K Sell
24,261
-1,257,363
-98% -$28.9M ﹤0.01% 1199
2020
Q4 		$22.5M Buy
1,281,624
+1,026,901
+403% +$18.5M 0.1% 232
2020
Q3 		$3.78M Buy
+254,723
New +$2.98M 0.02% 449

Other funds holding CLDX

RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
ACP
Acuta Capital Partners Redwood City, California $143M AUM 773.18% 1-Year Est. Return

Marshall Wace North America's CLDX Position: Q2 2021 in Review

Marshall Wace North America sold out of Celldex Therapeutics (CLDX) in Q2 2021, closing a stake of 24,261 shares — an estimated $500K sold.

Marshall Wace North America first reported a position in CLDX in Q3 2020 and held it in 3 quarters. The position peaked at $22.5M in Q4 2020. 131 funds tracked by Wall St. Rank hold CLDX as of Q2 2021.

  • Marshall Wace North America reported no remaining Celldex Therapeutics position as of Q2 2021 after selling out during the quarter.
  • Marshall Wace North America sold 24,261 Celldex Therapeutics shares in Q2 2021, an estimated $500K.
  • Marshall Wace North America first reported a position in Celldex Therapeutics in Q3 2020 and held it in 3 quarters.
  • Marshall Wace North America's Celldex Therapeutics position peaked at $22.5M in Q4 2020.
  • 131 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q2 2021.

Based on Marshall Wace North America's 13F filing for Q2 2021, filed 13 Aug 2021.